Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  NeuroOne Medical Technologies Corporation    NMTC

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

(NMTC)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

NeuroOne Medical Technologies : Announces Zimmer Biomet Distribution Deal For Its Evo(TM)

08/25/2020 | 04:49am EST

NeuroOne Medical Technologies Corporation (OTC: NMTC) has entered into a development and distribution deal that may be the first of more to come with Zimmer. In July, the company finalized an agreement with Zimmer Biomet (NYSE: ZBH) to market its Evo(TM) Cortical Electrode (Evo), the company's first FDA 510(k)-cleared product. The Evo Cortical Electrode is an innovative product indicated for recording, monitoring, and stimulating brain tissue for up to 30 days. Utilizing proprietary automated manufacturing processes, the thin-film lightweight design offers high-resolution capabilities, reduced immunological response-as demonstrated in pre-clinical studies-and the potential to be placed in a minimally invasive manner. NeuroOne has developed its products in collaboration with the University of Wisconsin-Madison'sAlumni Research Foundation and the Mayo Foundation for Medical Education and Research.

The terms of the deal give Zimmer Biomet the exclusive global right and license to distribute NeuroOne's strip and grid electrodes and electrode cable assembly products and the exclusive right and license to distribute certain depth electrodes developed by NeuroOne. In connection with the agreement, Zimmer Biomet made a $2 million upfront payment to NeuroOne. Additionally, in order to maintain its exclusive rights to distribute the depth electrodes, Zimmer Biomet must make an additional payment to NeuroOne according to the terms of the agreement.

That value can be recognized on at least two levels. On top of adding cash to its balance sheet, NeuroOne has established a working partnership with Zimmer. The deal with Zimmer is expected to free up NeuroOne's development team to focus on accelerating the development of new therapeutic technologies as well as provide additional capital to build the company infrastructure.

NeuroOne received its first FDA 510(k) clearance for its Evo(TM) Cortical Electrode product family in November of 2019. NeuroOne is also in late-stage development of a second hi-definition thin-film electrode product, its Evo(TM) sEEG Depth Electrode, a device that records brain activity placed through a minimally invasive procedure. Other products in pre-development and conceptual stages include an ablation electrode, a spinal cord stimulation electrode, and a deep brain stimulation electrode.

The most attractive feature of these products is that they each have the potential to deliver a best-in-class option to treatment professionals.

Video Link: https://www.youtube.com/embed/mtUw5KdqYO0

Balance Sheet Strengthened And Prepared To Grow In 2020

As NeuroOne faces the second half of 2020, it expects to be well-funded to advance through development and commercialization processes, as the company recently benefited from a more than $5 million private capital raise in addition to the upfront payment from Zimmer. That cash is expected to put the company in strong financial shape to direct its strategy of near term growth through product development and commercialization.

Great products often lead to great results, and NeuroOne expects it can deliver on both.

To find out more visit https://get.ceo3in60.com/neuroone/

Disclaimer

This communication was produced by PCG Digital Holdings, LLC, and affiliate of PCG Advisory Inc., (together "PCG"). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be 'Paid Advertising' for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the "Securities Act"). PCG may be compensated by respective clients for publicizing information relating to its client's securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures

Media Contact

Company Name: PCG Digital Holdings

Contact Person: Kenny Ellis

Email: info@ceo3in60.com

City: New York

State: New York

Country: United States

Website: https://pcgadvisory.com/

Source: www.abnewswire.com

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
NEUROONE MEDICAL TECHNOLOGIES CORPORATION 0.94% 1.07 Delayed Quote.-55.46%
ZIMMER BIOMET HOLDINGS 1.20% 147.85 Delayed Quote.-2.39%
All news about NEUROONE MEDICAL TECHNOLOGIES CORPORATION
10/06NEUROONE MEDICAL TECHNOLOGIES CORP : Other Events, Financial Statements and Exhi..
AQ
09/03NEUROONE MEDICAL TECHNOLOGIES CORP : Unregistered Sale of Equity Securities (for..
AQ
08/25NEUROONE MEDICAL TECHNOLOGIES : Announces Zimmer Biomet Distribution Deal For It..
AQ
08/13NEUROONE MEDICAL TECHNOLOGIES : Management's Discussion and Analysis of Financia..
AQ
08/06NEUROONE MEDICAL TECHNOLOGIES : Announces Distribution Deal With Zimmer Biomet F..
AQ
08/03NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
AQ
07/28NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
AQ
07/22NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
AQ
07/02NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
AQ
06/04NEUROONE MEDICAL TECHNOLOGIES CORP : Entry into a Material Definitive Agreement,..
AQ
More news
Financials (USD)
Sales 2019 - - -
Net income 2019 -6,78 M - -
Net cash 2019 0,26 M - -
P/E ratio 2019 -3,27x
Yield 2019 -
Capitalization 24,3 M 24,3 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 4
Free-Float 74,4%
Chart NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Duration : Period :
NeuroOne Medical Technologies Corporation Technical Analysis Chart | NMTC | US64130M1009 | MarketScreener
Income Statement Evolution
Managers
NameTitle
David A. Rosa President, Chief Executive Officer & Director
Paul R. Buckman Chairman
Steven Mertens Chief Technology Officer
Jeffrey S. Mathiesen Independent Director
Edward S. Andrle Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NEUROONE MEDICAL TECHNOLOGIES CORPORATION-55.46%23
SARTORIUS AG98.29%29 536
REVENIO GROUP OYJ58.86%1 333
CELLAVISION AB (PUBL)-7.36%831
ALPHATEC HOLDINGS, INC.44.19%802
VAREX IMAGING CORPORATION-44.65%644